Skip to main content

Latest stock market podcasts

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Morning Bell 17 January

Bell Direct
January 17, 2024

Morning Bell 16 January

Bell Direct
January 16, 2024

Morning Bell 15 January

Sophia Mavridis
January 15, 2024

Weekly Wrap 15 December

Bell Direct
December 15, 2023

Morning Bell 14 December

Bell Direct
December 14, 2023

Morning Bell 13 December

Bell Direct
December 13, 2023

Morning Bell 12 December

Bell Direct
December 12, 2023

Morning Bell 11 December

Bell Direct
December 11, 2023

Weekly Wrap 8 December

Bell Direct
December 8, 2023

Morning Bell 8 December

Bell Direct
December 8, 2023

Morning Bell 7 December

Bell Direct
December 7, 2023

Morning Bell 6 December

Bell Direct
December 6, 2023